06/03/03
200 3010 659

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
16 January 2003 (16.01.2003)

PCT

(10) International Publication Number
WO 03/004033 A1

(51) International Patent Classification[7]: A61K 31/485, 9/00, A61P 25/04

(21) International Application Number: PCT/US02/21403

(22) International Filing Date: 3 July 2002 (03.07.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/303,357	6 July 2001 (06.07.2001)	US
60/329,352	15 October 2001 (15.10.2001)	US
60/329,426	15 October 2001 (15.10.2001)	US

(71) Applicant: **PENWEST PHARMACEUTICALS COMPANY** [US/US]; 2981 Route 22, Patterson, NY 12563-9770 (US).

(72) Inventors: **BAICHWAL, Anand, R.**; 5 Kendell Drive, Wappingers Falls, NY 12590 (US). **KAO, Huai-Hung**; 137 Colony Lane, Syosset, NY 11791 (US). **MCCALL, Troy, W.**; 8861 Three Chimneys Drive East, Germantown, TN 38138 (US).

(74) Agents: **SUPERKO, Colleen** et al.; Hale and Dorr LLP, 60 State Street, Boston, MA 02109 (US).


(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*

[Continued on next page]

(54) Title: SUSTAINED RELEASE FORMULATIONS OF OXYMORPHONE



162162

(57) Abstract: Sustained release formulations of oxymorphone or pharmaceutically acceptable salts thereof; methods for making the sustained release formulations of oxymorphone or pharmaceutically acceptable salts thereof; and methods for using the sustained release formulations of oxymorphone or pharmaceutically acceptable salts thereof to treat patients suffering from pain are provided.

WO 03/004033 A1

ACTION

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.